Mycophenolic acid metabolite levels in pediatric liver transplantation: Correlation with a limited sampling strategy

Journal of Applied Research

Volumn 8, Issue 2, 2008, Pages 135-142

  Attard, Thomas M ^a   Dhawan, Anil ^b   Tredger, J Michael ^b   Conner, Kim ^a   Kling, Karen ^a   Colombani, Paul ^a   Thompson, Richard ^c   Cuffari, Carmen ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Liver transplantation; Metabolites; Mycophenolate mofetil; Pediatrics

Indexed keywords

CYCLOSPORIN; DRUG METABOLITE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; ASSAY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG METABOLISM; DRUG MONITORING; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MALE; MORNING DOSAGE; MULTICENTER STUDY; OPEN STUDY; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; REGRESSION ANALYSIS;

EID: 49149114781     PISSN: 1537064X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Blaheta RA, Leckel K, Wittig, B, et al. Mycophenolate mofetil impairs transendothelial migration of allogenic CD4 and CD8 T-cells. Transpl Proc. 1999;31:1250-1252.
2. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection, Transplantation. 2000;69:2405-2409.
3. Meier-Kriesche HU, Ojo AO, Leichtman AB, et al. Effect of mycophenolate mofetil on long-term outcome in African American renal transplant recipients. J Am Soc Nephrol. 2000;11:2366-2370.
4. Jain AB, Hamad I, Rakela J, et al.A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. Transplantation. 1998;66(10):1395-1398.
5. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int. 2001;59:1567-1573.
6. Weir MR, Anderson L, Fink JC, et al.A novel approach to the treatment of chronic allograft nephropathy. Transplantation. 1997;69:1749-1750.
7. Islam MS, Francos GC, Dunn SR, Burke JF Jr. Mycophenolate mofetil and reduction in cyclosporine dosage for chronic renal allograft dysfunction. Transplant Proc. 1998;30:2230-2231.
8. Pascual M, Williams WW, Cosimi AB, et al. Chronic renal allograft dysfunction: a role for mycophenolate mofetil? Transplantation. 2000;69:1749-1750.
9. Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS. Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation. 1999;68:158-161.
10. Butani L, Palmer J, Baluarte HJ, Polinsky MS. Adverse effects of mycophenolate mofetil in pediatric renal transplant recipients with presumed chronic rejection. Transplantation. 1999;68:83-86.
11. Fulton B, Markham A. Mycophenolate mofetil.A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs. 1996;51:278-298.
12. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. JAm Soc Nephrol. 1998;9:1511-1520.
13. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD,Wiesel M, Zimmerhackl LB, Staskewitz A, Schutz E, Mehls O, Oellerich M, Armstrong VW, Tonshoff B. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit. 1999;21:498-506.
14. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429-455.
15. Deters M, Kirschner G, Koal T, et al. Influence of cyclosporine on the serum concentration and biliary excretion of mycophenolic acid and 7-O-mycophenolic acid glucuronide. Ther Drug Monit. 2005;27:132-138.
16. Van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit. 2001;23:119-128.
17. Neu AM, Benfield M.What is the role for mycophenolate mofetil in pediatric renal transplantation. Pediatr Transplant. 1999;3:83-87.
18. Hong GK, Gulley ML, Feng WH, et al. Epstein-Barr virus infection contributes ease in a SCID mouse model. J Virol. 2005;79:13993-14003.
19. Weber LT, Schutz E, Lamersdorf T, et al. Therapeutic drug monitoring of total and free mycophenolic acid (MPA) and limited sampling strategy for determination of MPAAUC in pediatric renal transplant recipients. The German Study Group on Mycophenolate Mofetil (MMF) Therapy. Nephrol Dial Transplant. 1999;14(Suppl 4):34-35.
20. Leger F, Bouissou F, Coulais Y, et al. Estimation of glomerular filtration rate in children. Pediatr Nephrol. 2002;17:903-907.
21. Li S, Yatscoff RW. Improved high performance liquid chromatographic assay for the measurement of mycophenolic acid in human plasma. Transplant Proc. 1996;28:938-940.
22. Premaud A, Rousseau A, Le Meur Y, et al. Comparison of liquid chromatography-tandem mass spectrometry with a commercial enzyme-multiplied immunoassay for the determination of plasma MPA in renal transplant recipients and consequences for therapeutic drug monitoring. Ther Drug Monit. 2004;26:609-619.
23. Sainsbury EJ, Ashley JJ. Curve-fitting in pharmacokinetics - a comparison between gamma and biexponential fits. Eur J Clin Pharmacol. 1986;30:243-244.